ESMO Breast Cancer 2026 Highlights: Pumitamig + DB-1305/BNT325 - Report - MDSpire
Advertisement
ESMO Breast Cancer 2026 Highlights: Pumitamig + DB-1305/BNT325
Harold Burstein, MD, PhD, and Ana C. Garrido-Castro, MD discuss results from the Pumitamig + DB-1305/BNT325 trial, which were presented at the 2026 ESMO Breast Cancer Congress.
Clinical Report: ESMO Breast Cancer 2026 Highlights: Pumitamig + DB-1305/BNT325
Overview
The ESMO Breast Cancer Congress 2026 presented results from the Pumitamig + DB-1305/BNT325 trial, indicating antitumor activity in patients with advanced triple-negative breast cancer (TNBC). This trial involved a phase I/II expansion cohort of 30 patients.
Background
The treatment landscape for advanced triple-negative breast cancer (TNBC) is evolving, with a focus on novel therapeutic strategies such as bispecific immunomodulators and antibody-drug conjugates (ADCs). Understanding the efficacy of new combinations is crucial in a patient population with limited treatment options.
Data Highlights
No specific numerical data was provided in the source material.
Key Findings
Pumitamig is a bispecific immunomodulator targeting PD-L1 and VEGF-A.
DB-1305/BNT325 is an investigational TROP-2–directed antibody-drug conjugate.
The trial reported on 30 patients with advanced/metastatic TNBC.
Encouraging antitumor activity and durability of responses were noted.
The data were presented at the ESMO Breast Cancer Congress held in May 2026.
Clinical Implications
Continued research into the efficacy of Pumitamig and DB-1305/BNT325 is necessary.
Conclusion
The ESMO Breast Cancer Congress 2026 highlighted the potential of Pumitamig combined with DB-1305/BNT325 in treating advanced TNBC.
